Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Short of Cash, Northwest Bio Flirts With Insolvency

Short of Cash, Northwest Bio Flirts With Insolvency

The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.

Bristol-Myers Plunges on Shocking Immunotherapy Lung-Cancer Study Failure

Bristol-Myers Plunges on Shocking Immunotherapy Lung-Cancer Study Failure

A cancer immunotherapy shocker has Bristol-Myers Squibb tumbling and rival Merck soaring on Friday morning.